Xiaflex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of dupuytren’s contracture, rising awareness of non-surgical treatment alternatives, expansion of specialty biologics adoption, availability of trained healthcare professionals, growing acceptance of injectable therapies.

The growth in the forecast period can be attributed to increasing demand for outpatient biologic treatments, rising focus on reducing surgical interventions, expansion of personalized medicine approaches, growing geriatric population, continued innovation in collagen-targeting therapies. Major trends in the forecast period include increasing adoption of enzymatic non-surgical therapies, rising preference for minimally invasive treatment options, growing focus on targeted biologic injectables, expansion of physician-administered specialty therapies, enhanced emphasis on patient-specific treatment planning.

The rising prevalence of Peyronie’s disease is expected to drive growth in the Xiaflex market. Peyronie’s disease is a connective tissue disorder marked by fibrous plaque formation in the penis, causing curvature, pain, and functional issues. Its increasing prevalence is linked to factors such as aging, genetics, and injury-related tissue damage. Xiaflex is used to treat Peyronie’s disease by enzymatically breaking down fibrous plaques, improving penile curvature and function. For example, in February 2023, data from The Urology Care Foundation, a US-based organization affiliated with the American Urological Association, indicated that approximately 4 out of 100 men aged 40-70 are affected by Peyronie’s disease, with around 0.5% of adult American males formally diagnosed. Therefore, the growing prevalence of Peyronie’s disease is expected to fuel the Xiaflex market.

A key trend in the Xiaflex market is exploring alternative treatment protocols for resistant cases, including its use in surgical settings and expansion into other connective tissue disorders. Xiaflex is being investigated for potential benefits in surgery, aiming to reduce invasive procedures and improve recovery outcomes. For instance, in May 2024, Endo International Plc, a US-based pharmaceutical company, presented new data on Xiaflex for Peyronie’s disease at the American Urological Association (AUA) annual meeting. These studies, supported through Endo’s investigator-initiated research grants, evaluated Xiaflex versus surgery and explored protocols for patients who did not respond to previous treatments, reflecting the company’s commitment to improving clinical outcomes and expanding therapeutic applications.

In April 2024, Endo Inc., a US-based specialty pharmaceutical company, acquired the assets of Endo International Plc for an undisclosed amount. This acquisition created a new entity focused on growth through a diversified product portfolio, positioning Endo for sustained development and strategic expansion. Endo International Plc, the original company, continues to provide Xiaflex as part of its branded and generic drug offerings.

Major companies operating in the xiaflex market are Endo Inc.

North America was the largest region in the xiaflex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xiaflex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xiaflex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the xiaflex market by increasing costs associated with imported biologic raw materials, specialized enzymes, cold-chain logistics components, and pharmaceutical manufacturing equipment. Healthcare providers and specialty clinics in North America and Europe are most affected due to dependence on globally sourced biologic inputs, while Asia-Pacific faces pricing pressure on distribution and storage infrastructure. These tariffs contribute to higher treatment costs and reimbursement challenges. However, they are also encouraging localized biologics manufacturing, regional supply chain optimization, and investment in domestic pharmaceutical production capabilities to ensure long-term supply stability.

The xiaflex market research report is one of a series of new reports that provides xiaflex market statistics, including xiaflex industry global market size, regional shares, competitors with a xiaflex market share, detailed xiaflex market segments, market trends and opportunities, and any further data you may need to thrive in the xiaflex industry. This xiaflex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xiaflex (collagenase clostridium histolyticum) is a biologic injectable therapy used to treat Dupuytren’s contracture and Peyronie’s disease. It works by enzymatically breaking down the collagen responsible for tissue buildup and the contracture of affected tendons or plaques. The medication is administered via subcutaneous injection by a healthcare professional and is typically offered to patients who are not candidates for surgery or who prefer a non-surgical treatment option.

The main indications for Xiaflex include Dupuytren’s contracture, Peyronie’s disease, and other related conditions. Dupuytren’s contracture is characterized by thickened tissue beneath the skin of the palm, forming nodules that cause the fingers to bend inward; Xiaflex helps dissolve the collagen buildup, improving finger extension and hand function. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The xiaflex market consists of sales of single-use vials containing collagenase clostridium histolyticum for injectable use. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.